Some researchers at the Migal Galilee Research Institute
(MIGAL) in Israel say they have developed an effective vaccine against avian
coronavirus infectious bronchitis virus (IBV) and will soon create a human
vaccine against coronavirus (COVID-19).
IBV is a disease affecting animals. The researchers said the
vaccine against IBV has been proven in pre-clinical trials.
After four years of multi-disciplinary research funded by
Israel’s ministry of science and technology in cooperation with Israel’s
ministry of agriculture, MIGAL, on its website, the researchers said they have
achieved a scientific breakthrough that will lead to the rapid creation of a
vaccine against coronavirus.
MIGAL said it has now made required genetic adjustments to
adapt the vaccine to COVID-19, the human strain of coronavirus, and is working
to achieve the safety approvals that will enable in-vivo testing, enable the
initiation of production of a vaccine to counter the coronavirus epidemic
currently spreading throughout the world, which so far has claimed 2,666 lives.
From MIGAL research, it was discovered that the poultry
coronavirus has high genetic similarity to the human COVID-19, and that it uses
the same infection mechanism, a fact that increases the likelihood of achieving
an effective human vaccine in a very short period of time.
“Given the urgent global need for a human coronavirus
vaccine, we are doing everything we can to accelerate development. Our goal is
to produce the vaccine during the next 8-10 weeks, and to achieve safety
approval in 90 days,” David Zigdon, MIGAL’s chief executive officer, said.
“This will be an oral vaccine, making it particularly
accessible to the general public. We are currently in intensive discussions
with potential partners that can help accelerate the in-human trials phase and
expedite the completion final product development and regulatory activities.”
Chen Katz, MIGAL’s biotechnology group leader, also said
“the scientific framework for the vaccine is based on a new protein expression
vector, which forms and secretes a chimeric soluble protein that delivers the
viral antigen into mucosal tissues by self-activated endocytosis (a cellular
process in which substances are brought into a cell by surrounding the material
with cell membrane, forming a vesicle containing the ingested material),
causing the body to form antibodies against the virus. In pre-clinical
(IN-VIVO) trials, MIGAL’s researchers have demonstrated that the oral
vaccination induces high levels of specific anti-IBV antibodies.”
Nigeria confirmed its first case of the disease on Friday.
Click to signup for FREE news updates, latest information and hottest gists everyday
Advertise on NigerianEye.com to reach thousands of our daily users
No comments
Post a Comment
Kindly drop a comment below.
(Comments are moderated. Clean comments will be approved immediately)
Advert Enquires - Reach out to us at NigerianEye@gmail.com